FindTrial
Sign In

Expanded Access for Apixaban

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05187286
Enrollment
Unknown
Registered
2022-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is an expanded access designed to provide access to apixaban for eligible participants.

Interventions

DRUGApixaban

Administered as directed by treating physician

Sponsors

Bristol-Myers Squibb
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
28 Days to 17 Years

Inclusion criteria

* Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention * Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required

Exclusion criteria

* Weight less than 5 kg or greater than 35 kg Other inclusion/

Countries

United States

Contacts

Primary ContactRecruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Clinical.Trials@bms.complease email:
Backup ContactFirst line of the email MUST contain NCT # and Site #.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026